Vera Therapeutics reports FY 2025 net loss $299.6M; FDA priority review for atacicept PDUFA July 7, 2026

Vera Therapeutics, Inc.

2025-FY EPS reported -$4.66

Net loss of $299.6M (diluted EPS -$4.66), vs $152.1M loss in FY 2024.
Cash, equivalents, and marketable securities $714.6M as of Dec 31, 2025, expected to fund through atacicept launch.
FDA granted priority review for atacicept BLA in IgA nephropathy; PDUFA date July 7, 2026.
Completed $800M equity/debt financings; potential U.S. commercial launch mid-2026 if approved.
Appointed James R. Meyers to Board; Phase 2 PIONEER basket trial results expected 1H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.